Calcium-phosphate homeostasis in secondary progressive multiple sclerosis patients during mitoxantrone therapy

References

• Saini V, Nadeem M, Kolb C, et al. Vitamin D: Role in pathogenesis of multiple sclerosis. In: Minagar A, editor. Multiple sclerosis a mechanistic view. Amsterdam: Academic Press; 2016. p. 127–152.
   Google Scholar
• Al-Mahdawi AM, Al Gawwam G, Al Ethawi RA. Association of Vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. IRAQI Postgrad Med J. 2014 Nov 24;3(2):298–305.
   Google Scholar
• Doosti-Irani A, Tamtaji OR, Mansournia MA, et al. The effects of vitamin D supplementation on expanded disability status scale in people with multiple sclerosis: a critical, systematic review and metaanalysis of randomized controlled trials. Clin Neurol Neurosurg [Internet]. 2019;187(July):1–5.
   Google Scholar
• Kamm CP, Uitdehaag M, Polman CH. Multiple sclerosis : Current knowledge and futue outlook. Eur Neurol. 2014;72(3–4):132–141.
   PubMed Web of Science ®Google Scholar
• Wawrzyniak S, Rzepiński Ł. Is there a new place for mitoxantrone in the treatment of multiple sclerosis? Neurol Neurochir Pol. 2020;54(1):54–61.
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Multiple Sclerosis Review. Pharm Ther. 2012;37(3):175–184.
   Google Scholar
• Alharbi FM. Update in vitamin D and multiple sclerosis. Neurosciences. 2015;20(4):329–335.
   PubMed Web of Science ®Google Scholar
• Smolders J, Ø T, Camu W, et al. Update on vitamin d and disease activity in multiple sclerosis. CNS Drugs [Internet]. 2019;33(12):1187–1199.
   PubMed Web of Science ®Google Scholar
• Brola W. Profile of Polish patients with progressive forms of multiple sclerosis. MS Rep. 2019;8(3):5–11.
   Google Scholar
• Esposito F, Martinelli V, Sormani MP, et al. Comparative study of mitoxantrone efficacy profile in patients with relapsing–remitting and secondary progressive multiple sclerosis. Mult Scler. 2010;16(12):1490–1499.
   PubMed Web of Science ®Google Scholar
• Basit BS. Vitamin D in health and disease: a literature review. Br J Biomed Sci. 2013;70(4):161–172. 2013.
   PubMed Web of Science ®Google Scholar
• Trautvetter U, Neef N, Leiterer M, et al. Effect of calcium phosphate and vitamin D3 supplementation on bone remodelling and metabolism of calcium, phosphorus, magnesium and iron. Nutr J. 2014;13(6):1–9.
   PubMedGoogle Scholar
• Harbo HF, Gold R, Tintoré M. Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord. 2013;6(4):237–248.
   PubMed Web of Science ®Google Scholar
• Moen SM, Celius EG, Sandvik L, et al. Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: A population-based case-control study. PLoS One. 2012;7(9):e45703.
   PubMed Web of Science ®Google Scholar
• Bäcker-Koduah P, Bellmann-Strobl J, Scheel M, et al. Vitamin D and disease severity in multiple sclerosis—baseline data from the randomized controlled trial (EVIDIMS). Front Neurol. 2020;11:(February):1–6.
   PubMedGoogle Scholar
• Čierny D, Michalik J, Škereňová M, et al. ApaI, BsmI and TaqI VDR gene polymorphisms in association with multiple sclerosis in Slovaks. Neurol Res [Internet]. 2016;38(8):678–684.
   PubMed Web of Science ®Google Scholar
• Čierny D, Michalik J, Kurča E, et al. FokI vitamin D receptor gene polymorphism in association with multiple sclerosis risk and disability progression in Slovaks. Neurol Res. 2015;37(4):301–308.
   PubMed Web of Science ®Google Scholar
• Płudowski P, Ducki C, Konstantynowicz J, et al. Vitamin D status in Poland. Pol Arch Med WEWNĘTRZNEJ. 2016;126(7–8):530–539.
   Google Scholar
• Skalli A, Eh ABH, El JR, et al. Association of vitamin D status with multiple sclerosis in a case-control study from Morocco Original article Association of vitamin D status with multiple sclerosis in a case-control study from Morocco. Rev Neurol (Paris). 2018;174(3):149–155.
   Web of Science ®Google Scholar
• Kubicka-Baczyk K, Labuz-Roszak B, Pierzchala K, et al. Calcium-phosphate metabolism in patients with multiple sclerosis. J Endocrinol Invest. 2015;38(6):635–642.
   PubMed Web of Science ®Google Scholar
• Dionyssiotis Y. Bone loss and fractures in multiple sclerosis : focus on epidemiologic and physiopathological features. Int J Gen Med. 2011;4:505–509.
   PubMedGoogle Scholar
• Golan D, Halhal B, Glass-marmor L, et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol [Internet]. 2013;13(60):1–10. Available from: BMC Neurology.
   PubMedGoogle Scholar
• Sternberg Z. Cardiovascular autonomic dysfunction: link between multiple sclerosis osteoporosis and neurodegeneration. NeuroMolecular Med. 2018;20(1):37–53. Internet.
   PubMed Web of Science ®Google Scholar
• Sozen T, Ozisik L, Calik Basaran N. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46–56.
   PubMed Web of Science ®Google Scholar
• Bazelier MT, Van ST, Uitdehaag BMJ, et al. J BMR the risk of fracture in patients with multiple sclerosis : The UK general practice research database. J Bone Miner Res. 2011;26(9):2271–2279.
   PubMed Web of Science ®Google Scholar
• Dabbaghmanesh MH, Yousefipour GA. Bone loss with multiple sclerosis: effect of glucocorticoid use and functional status. Iran Red Crescent Med J. 2011;13(1):9–14.
   PubMed Web of Science ®Google Scholar
• Tüzün S, Altintaş A, Karacan I, et al. Bone status in multiple sclerosis: beyond corticosteroids. Mult Scler. 2003;9(6):600–604.
   PubMedGoogle Scholar
• Miclea A, Bagnoud M, Chan A, et al. Review of the effects of vitamin D on multiple sclerosis. Front Immunol. 2020;11(May):1–10.
   PubMedGoogle Scholar
• Delavar MA, Lye MS, Hassan STBS, et al. Physical activity, nutrition, and dyslipidemia in middle-aged women. Iran J Public Health. 2011;40(4):89–98.
   PubMed Web of Science ®Google Scholar
• Mitoxantrone. LiverTox clin res inf drug-induced liver inj [internet] bethesda natl inst diabetes dig kidney dis 2012- mitoxantrone [ Updated 2020 Feb 19].
   Google Scholar
• Findling O, Hauer L, Pezawas T, et al. Cardiac autonomic dysfunction in multiple sclerosis : a systematic review of current knowledge and impact of immunotherapies. J Clin Med Rev. 2020;9(335):1–25.
   Google Scholar
• Ż P, Tomczykiewicz K, Piusińska-macoch R, et al. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis. Kardiol Pol. 2016;74(4):380–384.
   PubMed Web of Science ®Google Scholar
• Mincu RI, Magda SL, Mihaila S, et al. Impaired cardiac function in patients with multiple sclerosis by comparison with normal subjects. Sci Rep [Internet]. 2018;8(3300):1–8.
   PubMedGoogle Scholar